To examine the role of BRAF in the adjuvant stage II/III disease setting, Popovici and colleagues performed differential gene expression analysis to identify transcriptional differences between BRAFMT and BRAFWT/KRASWT tumors in a cohort of 688 stage II and III colon cancer (CC) clinical trial samples (PETACC-3) [7]. This evidence concerns the gene BRAF and malignant colon neoplasm.